VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decrease in Short Interest

VivoSim Labs, Inc. (NASDAQ:VIVS) was the recipient of a large drop in short interest in December. As of December 15th, there was short interest totaling 25,097 shares, a drop of 34.6% from the November 30th total of 38,358 shares. Approximately 1.0% of the shares of the stock are short sold. Based on an average daily volume of 44,418 shares, the days-to-cover ratio is currently 0.6 days. Based on an average daily volume of 44,418 shares, the days-to-cover ratio is currently 0.6 days. Approximately 1.0% of the shares of the stock are short sold.

VivoSim Labs Stock Performance

VivoSim Labs stock opened at $2.01 on Friday. The firm has a market cap of $5.25 million, a price-to-earnings ratio of -0.46 and a beta of 1.27. VivoSim Labs has a 1 year low of $1.41 and a 1 year high of $21.96. The firm’s 50 day moving average price is $2.23 and its two-hundred day moving average price is $2.29.

VivoSim Labs (NASDAQ:VIVS) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.98) EPS for the quarter. The company had revenue of $0.03 million for the quarter. VivoSim Labs had a negative net margin of 1,413.57% and a negative return on equity of 28.83%.

Hedge Funds Weigh In On VivoSim Labs

An institutional investor recently bought a new position in VivoSim Labs stock. Two Sigma Investments LP purchased a new position in VivoSim Labs, Inc. (NASDAQ:VIVS) during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 23,192 shares of the company’s stock, valued at approximately $68,000. Two Sigma Investments LP owned approximately 0.89% of VivoSim Labs at the end of the most recent quarter. 8.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VivoSim Labs in a research note on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, VivoSim Labs has an average rating of “Sell”.

VivoSim Labs Company Profile

VivoSim Labs, Inc (NASDAQ: VIVS) is a biotechnology company specializing in the development and commercialization of advanced 3D human tissue models for preclinical drug testing and disease modeling. The company’s proprietary organoid platforms and cell-based assays are designed to replicate human physiological environments, enabling more predictive evaluation of drug efficacy, safety, and toxicity before clinical trials. By integrating cutting-edge bioengineering and microfluidics technologies, VivoSim Labs seeks to bridge the gap between traditional cell culture methods and human clinical outcomes.

The company’s product portfolio includes 3D bioprinted tissues, organ-on-a-chip systems, and disease-specific models targeting key therapeutic areas such as oncology, cardiology, and hepatology.